高盛上调诺诚健华-B(09969.HK)目标价至21元评级「买入」

AAFN2021-03-30

高盛发表研究报告指，诺诚健华-B 去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行指，诺诚健华在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，高盛认为今年下半年潜在的国家医保药品目录谈判或...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2123267208?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","is_english":false,"pubTime":"2021-03-30 14:01","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2123267208","market":"us","top_or_hot":-1,"title":"高盛上调诺诚健华-B(09969.HK)目标价至21元  评级「买入」","media":"AAFN","content":"<div>\n<p>高盛发表研究报告指，诺诚健华-B  去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行指，诺诚健华在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，高盛认为今年下半年潜在的国家医保药品目录谈判或...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛上调诺诚健华-B(09969.HK)目标价至21元  评级「买入」</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛上调诺诚健华-B(09969.HK)目标价至21元  评级「买入」\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 14:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表研究报告指，诺诚健华-B  去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行指，诺诚健华在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，高盛认为今年下半年潜在的国家医保药品目录谈判或...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2123267208","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2123267208","pubTimestamp":1617084088,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"高盛发表研究报告指，诺诚健华-B  去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。高盛对诺诚健华予以「买入」评级，以反映2月份配股所得资金，以及公司将於今明两年加大研发投入，但预期今年及明年净亏损5.85亿及3.01亿元人民币，目标价上调至21元。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09969":"诺诚健华"},"translate_title":"Goldman Sachs raised the target price of Nuocheng Jianhua-B (09969. HK) to 21 yuan's rating of \"buy\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"90009":1,"09969":1},"content_text":"高盛发表研究报告指，诺诚健华-B  去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行指，诺诚健华在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，高盛认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一，参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价，认为对BTK抑制剂市场价格有支持作用。高盛对诺诚健华予以「买入」评级，以反映2月份配股所得资金，以及公司将於今明两年加大研发投入，但预期今年及明年净亏损5.85亿及3.01亿元人民币，目标价上调至21元。(gc/t)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2123267208"}

高盛上调诺诚健华-B(09969.HK)目标价至21元 评级「买入」

精彩评论

高盛上调诺诚健华-B(09969.HK)目标价至21元评级「买入」